Wearable Device Cuts AFib Recurrence by 57% After Ablation
A wrist-worn device significantly reduced atrial fibrillation recurrences in a pilot study, with no serious adverse events.
Key points
- NeuroPulse study showed 12 arrhythmia events with treatment vs. 28 with sham, a statistically significant reduction.
- The device achieved 90% freedom from atrial arrhythmias at six months, compared to 80.8% in the control group.
- No serious adverse events were reported, though the pilot study requires larger trials to confirm efficacy.
A new pilot study suggests that a wrist-worn device can significantly reduce the return of atrial fibrillation after standard ablation procedures. The research, published in Heart Rhythm, found that patients using the non-invasive neuromodulation tool experienced far fewer arrhythmia events than those using a placebo device.
The findings were presented at HRX Live 2026 by Dr. Vivek Reddy of Mount Sinai Hospital. While the study is a small pilot, the results indicate a potential new avenue for managing a condition that often recurs despite advanced surgical treatments.
Study shows significant event reduction
In the NeuroPulse pilot, patients receiving median nerve stimulation had 12 recurrent arrhythmia events compared to 28 in the sham group. This represents a substantial drop in recurrence rates, with a p-value of 0.025 indicating statistical significance. The study also reported a 90 percent freedom from arrhythmias at six months, compared to 80.8 percent in the control group.
Crucially, the study reported no serious adverse events linked to the device or the stimulation. This safety profile is notable for a wearable medical device intended for long-term use. The data was released via prnewswire.com and simultaneously submitted to peer review, highlighting the immediate clinical interest in the results.
Neuromodulation targets nerve pathways
Unlike ablation, which destroys heart tissue to stop electrical signals, this device stimulates the median nerve to influence autonomic regulation. Dr. Reddy explained that ablation is effective but leaves a persistent efficacy gap for many patients. This approach offers a different biological mechanism rather than simply adding more energy to the heart.
The device, developed by StimCardio, is designed as a physician-prescribed adjunct to existing treatments. It uses continuous physiological sensing to deliver personalized stimulation. This allows for care that extends beyond the hospital into daily life, addressing the limitations of one-time procedural interventions.
Pilot results need larger trials
Despite the promising numbers, the study is a small, three-center pilot. Dr. Reddy emphasized that these findings warrant confirmation in a larger, multi-center clinical trial. The current data provides a strong clinical signal but is not yet definitive proof of long-term efficacy.
The company plans to move forward with a pivotal trial to validate these initial results. Until then, the device remains investigational and not available for standard clinical use. The trade-off is clear: this is a potential breakthrough, but it requires further rigorous testing to become a standard of care.
